Coinbase announced it will halt all transfers of GYEN, a yen-pegged stablecoin, on October 26, 2026. After this date, any remaining GYEN balances on the platform will be automatically converted to USD Coin (USDC) at prevailing market rates, reflecting Coinbase's shift away from non-dollar stablecoins. Users must transfer or withdraw their GYEN before the deadline if they want to keep it, as the conversion will not offer yen fiat or other assets. This move highlights Coinbase's focus on dollar-pegged stablecoins amid regulatory and commercial pressures in the U.S. market.
Regarding Coinbase's plan to halt GYEN transfers and convert balances to USDC, here is Pluang's market snapshot as of Oct 24, 2026 02:31 WIB: Among 50 major cryptocurrencies priced on Pluang, 36 rose and 13 fell today. Notable movers include LUNC (Terra Classic) at Rp0,832 with a 2.50% increase and a typical hold time of 195 days, ETC (Ethereum Classic) at Rp141.197 with a 2.19% rise and 100% buy order activity, and FTM (Fantom) at Rp11.382 with a 2.05% decline and a typical hold time of 88 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
